Define Your Tomorrow with the Power of Partnership: Beckman Coulter Diagnostics Brings Clinical Innovations to 70th AACC Annual Meeting and Clinical Laboratory Expo

Beckman Coulter Diagnostics goes beyond technology to help laboratories face challenges in the current healthcare environment

BREA, Calif. — (July 20, 2018) — Beckman Coulter, a global leader in the clinical diagnostics industry, will be featuring over a dozen of its newest innovations and differentiated solutions at the 70th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Laboratory Expo (CLE) in Chicago, Illinois. Featured at the event will be two new hematology analyzers—the high-volume DxH 900 with Early Sepsis Indicator* and the low-volume DxH 520*—as well as the high-sensitivity troponin I assay, Access hsTnI, for use on the Access 2 and DxI family of immunoassay systems. In addition to these new products, Beckman Coulter will showcase their comprehensive portfolio, including the Power Express laboratory automation system, with a full complement of clinical information technology solutions. The combination of innovation and solutions showcases the central theme of “Define Your Tomorrow with the Power of Partnership.”

Diagnostic innovations for critical conditions, including sepsis and acute myocardial infarction, will be the featured topics at Beckman Coulter’s in-booth theater presentations. The attendees will have the opportunity to learn about the recently released Beckman Coulter high-sensitivity troponin I assay, for diagnosis of patients presenting with chest pain, and Early Sepsis Indicator, for which Beckman Coulter recently filed a 510(k) submission to the U.S. FDA.

“Access hsTnI, the first true high-sensitivity troponin I assay cleared by the FDA, demonstrates <10% cv at the upper reference limits (urls) for men and women, and detects troponin in >50% of the healthy population. With this assay, laboratories have increased testing flexibility, as it is the only high-sensitivity assay to use either plasma or serum samples,” said Puneet Sarin, senior vice president and general manager, chemistry and immunoassay, Beckman Coulter Diagnostics.

“The most common cause of death in women is heart disease. Women sometimes do not exhibit the same symptoms as men when experiencing a heart attack. Because women tend to have lower troponin levels than men, their treatment may be delayed,” said Michael Samoszuk, M.D., vice president and chief medical officer, Beckman Coulter Diagnostics. “Access hsTnI enables more accurate identification of women with myocardial infarction by providing separate sex-specific URLs.”

“Actionable diagnostic information in the shortest possible time is critical for patients with high-acuity conditions,” said Peter Soltani, senior vice president and general manager, hematology, Beckman Coulter Diagnostics. “The Early Sepsis Indicator is a first-of-its-kind hematologic parameter that can be calculated as part of the standard CBC test on DxH 900 systems. It gives clinicians an insight into the possibility of sepsis, or risk of developing sepsis, in patients in acute-care settings. Given the mortality and financial burden of sepsis worldwide, we believe that this new parameter will help advance the care of septic patients just as Coulter analyzers impacted clinical practice over 60 years ago.”

“Decreasing reimbursement, increasing workloads, and shortages of qualified technologists are just a few of the challenges seen by clinical laboratories today,” said Chris Riley, president, Beckman Coulter Diagnostics. “Our singular focus is serving clinical laboratories and their patients. Beckman Coulter’s broad product portfolio, Performance Partnership program and cadence of clinical innovations make us uniquely positioned to help laboratories succeed in the current environment.”

Laboratorians and healthcare professionals can learn more about Beckman Coulter Diagnostics solutions by participating in educational programs and in-booth presentations listed below. Detailed information is available at

AACC/CLE 2018 Beckman Coulter In-booth Theater Presentations

Begin on the hour; 30–35-minute presentation followed by 10–15-minute Q&A

Embracing High-sensitivity Troponin from the Lab's Perspective
Robert H. Christenson, Ph.D., DABCC, FACB
2013 President, AACC
Professor of Pathology
Professor of Medical and Research Technology
University of Maryland School of Medicine, Baltimore, Maryland

Tuesday, July 31, 10:00 a.m., and Wednesday, August 1, 2:00 p.m.

Risk Assessment for Sepsis with Procalcitonin

Thomas K. Bane, Ph.D., PPM
Global Medical and Scientific Affairs
Beckman Coulter Diagnostics

Tuesday, July 31, 11:00 a.m., and Wednesday, August 1, 3:00 p.m.

Early Sepsis Indicator—Better Answers, Sooner

Michael Waite
Senior Product Manager
Beckman Coulter Diagnostics

Tuesday, July 31, 12:00 p.m., and Wednesday, August 1, 4:00 p.m.

The Ovarian Reserve Story: Understanding the Value of AMH

Lindsay Sun, M.D., M.S.
Senior Scientific Affairs Manager
Beckman Coulter Diagnostics

Tuesday, July 31, 1:00 p.m., and Wednesday, August 1, 11:00 a.m.

New Assays for Use in the Opiate Crisis: 6-Acetylmorphine and Buprenorphine

Global Medical and Scientific Affairs
Beckman Coulter Diagnostics

Tuesday, July 31, 2:00 p.m., and Wednesday, August 1, 1:00 p.m.

Antimicrobial Stewardship

Barbara Zimmer, Ph.D.
Principal Scientist
Beckman Coulter Diagnostics

Tuesday, July 31, 3:00 p.m., and Wednesday, August 1, 10:00 a.m.

VCS and DataFusion Technologies—Near Native-state Cellular Characterization

Ahmed Bentahar, M.D., Ph.D.
Senior Manager, Global Scientific Marketing
Beckman Coulter Diagnostics

Tuesday, July 31, 4:00 p.m., and Wednesday, August 1, 12:00 p.m.

Joint Industry Sponsored Workshop
New Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome

Wednesday, August 1, 7:00–8:30 a.m. │ Grand Horizon Ballroom (A-C) Level 4
Marriott Marquis Chicago │ 2121 South Prairie Ave. │ Chicago

About Beckman Coulter
Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. With a rich 80-year history, Beckman Coulter is a strong partner for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person.


*CE marked. Pending 510(k) clearance by the U.S. FDA. Not yet available for in vitro diagnostic use in the U.S.
© 2023 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.